



#26
amendtc

Express Mail No.: EL 477 037 277 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
OCT 17 2002
TECH CENTER 1600/2900

Application of: Xu et al.

Confirmation No.: 1781

Application No.: 09/026,459

Group Art Unit: 1632

Filed: February 19, 1998

Examiner: R. R. Shukla

For: **MODIFIED RETINOBLASTOMA
TUMOR SUPPRESSOR PROTEINS**

Attorney Docket No.: 8660-025

AMENDMENT UNDER 37 C.F.R. § 1.116

Assistant Commissioner for Patents
Box AF
Washington, D.C. 20231

Sir:

In response to the final Office Action mailed April 10, 2002, please enter the amendments and consider the remarks below in connection with the above-identified patent application. Applicants submit herewith (a) Exhibit A: a marked up version of the claims showing the amendments made herein; (b) Exhibit B: pending claims upon entry of present amendment; (c) a Petition for an Extension of Time for filing a Response for three months from July 10, 2002 up to and including October 10, 2002, accompanied by the appropriate fee; (d) an Amendment Fee Transmittal Sheet; (e) a Supplemental Information Disclosure Statement; (f) a List of References Cited by Applicant; (g) copies of references A4 and C38-C49; and (h) a Request for Continued Examination.

IN THE CLAIMS:

Please amend the claims as follows:

Cancel claims ~~2-10~~, ~~13~~, ~~14~~, ~~16-20~~, ~~31-34~~, and ~~44-48~~ without prejudice.

Amend claims 1, 11, 12, 21, 22, 23, 24, 25, 26, 27, and 36 as follows:

1 (thrice amended). A DNA segment comprising an isolated nucleic acid,
wherein said nucleic acid comprises a nucleotide sequence selected from the group consisting
C1 of SEQ ID NO:28; SEQ ID NO:30; SEQ ID NO:32; SEQ ID NO:34; SEQ ID NO:36; SEQ

10/16/2002 AMONDAF1 00000002 161150 09026459

03 FC:2201
04 FC:2202

84.00 CH
27.00 CH

NY2 - 1344706.1